Skip to content

Organon & Co. (OGN) stock: revenue, earnings & dividend

Organon & Co. (OGN, NYSE): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener OGN · NYSE Pharma & Biotech US-NJ

Key figures

Fiscal year
2025
Revenue
6.22 bn $
Revenue growth
-2.9 %
Revenue growth 5y (p.a.)
-1 %
Net income
187 m $
Net margin
3 %
Operating margin
–
Earnings per share (diluted)
0.72 $
Dividend per share
0.34 $
Payout ratio
47.2 %
Consecutive dividend years
5 years
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
12.9 bn $
Equity
752 m $
Equity ratio
5.8 %
Return on equity
24.9 %
Cash
574 m $
Operating cash flow
700 m $
Free cash flow
538 m $
Shares outstanding
262,621,584

History

Revenue by fiscal year

2019 7.78 bn $
2020 6.53 bn $
2021 6.3 bn $
2022 6.17 bn $
2023 6.26 bn $
2024 6.4 bn $
2025 6.22 bn $

Net income by fiscal year

2019 3.22 bn $
2020 2.16 bn $
2021 1.35 bn $
2022 917 m $
2023 1.02 bn $
2024 864 m $
2025 187 m $

Dividend per share

2021 0.19 $
2022 0.37 $
2023 0.37 $
2024 0.37 $
2025 0.34 $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20256.22 bn $187 m $0.72 $0.34 $700 m $
20246.4 bn $864 m $1.11 $0.37 $939 m $
20236.26 bn $1.02 bn $1.33 $0.37 $799 m $
20226.17 bn $917 m $1.20 $0.37 $858 m $
20216.3 bn $1.35 bn $1.77 $0.19 $–
20206.53 bn $2.16 bn $8.52 $––
20197.78 bn $3.22 bn $12.69 $––

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)